Dr. Reddy's Laboratories Ltd. (RDY)

37.84
0.18 0.47
NYSE : Health Technology
Prev Close 38.02
Open 37.99
Day Low/High 37.45 / 38.29
52 Wk Low/High 28.49 / 42.82
Volume 190.95K
Avg Volume 172.40K
Exchange NYSE
Shares Outstanding 166.01M
Market Cap 6.50B
EPS 0.90
P/E Ratio 40.67
Div & Yield 0.27 (0.74%)
Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's today announced the launch of Nise D Spray, emphasizing its strategic intent of being a player of substance in the Indian OTC (Over The Counter) space.

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half year ended September 30, 2015 on Thursday, October 29, 2015 after the Board Meeting.

Dr Reddy Laboratories (RDY) Showing Signs Of Being Strong And Under The Radar

Dr Reddy Laboratories (RDY) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Announces The Launch Of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 Mg And 40 Mg

Dr. Reddy's Announces The Launch Of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 Mg And 40 Mg

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM ® (esomeprazole...

Dr. Reddy's Laboratories Signs Commercialization Deal With Hatchtech

Dr. Reddy's Laboratories Signs Commercialization Deal With Hatchtech

Dr. Reddy's Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™...

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx, Inc., a global medical nutrition company based in Boulder, Colorado, and Dr.

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx, Inc., a global medical nutrition company based in Boulder, Colorado, and Dr.

Today's Weak On High Volume Stock: Dr Reddy Laboratories (RDY)

Today's Weak On High Volume Stock: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

Dr. Reddy's Announces Management Changes

Dr. Reddy's Announces Management Changes

Dr. Reddy's Laboratories (NYSE: RDY) today announced the following senior level changes in their global management structure.

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Announces The Launch Of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets

Dr. Reddy's Announces The Launch Of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.

Dr. Reddy's Announces Strategic Collaboration With Amgen In India

Dr. Reddy's Announces Strategic Collaboration With Amgen In India

Dr. Reddy's Laboratories Ltd.

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

New Lifetime High For Dr Reddy Laboratories (RDY)

New Lifetime High For Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q1FY16 Results On July 30, 2015 // Earnings Call Slated For July 30, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q1FY16 Results On July 30, 2015 // Earnings Call Slated For July 30, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2015 on Thursday, July 30, 2015 after the Board Meeting.

New Lifetime High For Dr Reddy Laboratories (RDY)

New Lifetime High For Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Announces The Launch Of MEMANTINE HYDROCHLORIDE TABLETS, USP

Dr. Reddy's Announces The Launch Of MEMANTINE HYDROCHLORIDE TABLETS, USP

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA® (memantine HCl) tablets in the US...

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CHW, CEN, RDY

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CHW, CEN, RDY

CHW CEN RDY are going ex-dividend tomorrow, Wednesday, July 08, 2015

Dr. Reddy's Unveils New Corporate Brand Identity

Dr. Reddy's Unveils New Corporate Brand Identity

Dr. Reddy's Laboratories (NYSE: RDY) today announced the launch of its new visual identity and brand, that will guide its actions across the globe: Good Health Can't Wait.

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2015, was filed with the United...

3 Stocks Boosting The Drugs Industry Higher

3 Stocks Boosting The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Dr. Reddy's Q4 & FY15 Financial Results

Dr. Reddy's Q4 & FY15 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q4 And Full Year FY15 Results On May 12, 2015

Dr. Reddy's To Release Q4 And Full Year FY15 Results On May 12, 2015

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter and Full Year ended March 31, 2015 on Tuesday, May 12, 2015 after the Board Meeting.

Dr Reddy Laboratories (RDY) Weak On High Volume

Dr Reddy Laboratories (RDY) Weak On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

3 Large-Cap Pharmaceutical Companies to Invest in Right Now

3 Large-Cap Pharmaceutical Companies to Invest in Right Now

Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.

Dr. Reddy's Laboratories And Its Subsidiary Promius PharmaTM Announce The Filing Of Three NDAs With The USFDA

Dr. Reddy's Laboratories And Its Subsidiary Promius PharmaTM Announce The Filing Of Three NDAs With The USFDA

Dr. Reddy's Laboratories (NYSE:RDY) and its subsidiary, Promius Pharma™, LLC today announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.

TheStreet Quant Rating: B (Buy)